Skip to main content
Back
Watch Compare

Silexion Therapeutics Corp

Data quality: 83%
Also listed as SLXNW NASDAQ
SLXN
NASDAQ Manufacturing Chemicals
$1.05
▼ $0.06 (-5.41%)
Mkt Cap: 3.70 M
Price
$1.11
Mkt Cap
3.70 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -10.83 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-335.69%
Below sector avg (-53.58%)
ROIC-147.32%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio3.97
Interest CoverageN/A

Valuation

PE (TTM)
-0.31
Above sector avg (-1.48)
P/B Ratio0.53
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E -0.3 -1.5
P/B 0.5 1.6
ROE % -335.7 -53.6
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

2 analysts
Strong Buy
Current
$1.05
+471.4%
Target
$6.00
$6.00
$6.00
$6.00
Forecast
Forward EPS -$2.87
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$2.87
-$3.50 – -$2.23
 0.0 2
FY2026 -$4.12
-$4.55 – -$3.69
 0.0 2

Earnings Surprises

Last 2 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$1.12 N/A —
Q32025 -$3.40 -$2.88 +15.3%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -11.91 M
ROE -335.69% ROA -136.83%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -10.83 M
ROIC -147.32% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.97
Interest Coverage N/A Asset Turnover N/A
Working Capital 8.27 M Tangible Book Value 6.98 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.31 Forward P/E N/A
P/B Ratio 0.53 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -292.87%
Market Cap 3.70 M Enterprise Value -5.55 M
Per Share
EPS (Diluted TTM) 8.96 Revenue / Share N/A
FCF / Share -3.25 OCF / Share -3.25
EPS CAGR (1Y) -66.01% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 90.90%
SBC-Adj. FCF -10.99 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue — —
Net Income -11.91 M -16.52 M
EPS (Diluted) 8.96 26.36
Gross Profit — —
Operating Income -11.63 M -12.57 M
EBITDA — —
R&D Expenses 7.14 M 5.82 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax 3,000.0 10,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 7.22 M 2.86 M
Total Liabilities 4.61 M 6.85 M
Shareholders' Equity 2.60 M -3.99 M
Total Debt — —
Cash & Equivalents 5.99 M 1.19 M
Current Assets 6.64 M 2.25 M
Current Liabilities 2.76 M 3.52 M